Licensed ICS/LABA combination treatments for asthma Relvar Components (ICS/LABA) Inhaler Indication Seretide2, 3 Symbicort4-6 Fostair7 Fluticasone Furoate/ Vilanterol Fluticasone Propionate/ Salmeterol Budesonide/ Formoterol Beclometasone Dipropionate/ Formoterol Fluticasone Propionate/ Formoterol DPI, Ellipta DPI, Accuhaler MDI, Evohaler DPI, Turbohaler MDI MDI Regular treatment of asthma where the use of a combination ICS & LABA is appropriate: Regular treatment of asthma where the use of a combination ICS & LABA is appropriate: Regular treatment of asthma where the use of a combination ICS & LABA is appropriate: Patients not adequately controlled with ICS and ‘as needed’ SABA OR Patients not adequately controlled with ICS and ‘as needed’ SABA OR Patients not adequately controlled with ICS and ‘as needed’ SABA OR 1 Regular treatment of asthma Regular treatment of asthma in adults and adolescents where the use of a combination where the use of a ICS & LABA is appropriate: combination ICS & LABA is appropriate: Patients not adequately controlled with ICS and ‘as Patients not adequately needed’ SABA controlled with ICS and ‘as OR needed’ SABA Patients already adequately controlled on both an ICS and LABA Doses (mcg) Administration Flutiform 8 Patients already adequately Patients already adequately Patients already adequately controlled on both an ICS and controlled on both an ICS controlled on both an ICS and LABA and LABA LABA 92/22, 184/22 Accuhaler: 100/50, 250/50, 500/50 Evohaler: 50/25, 125/25, 250/25 100/6, 200/6, 400/12 100/6 50/5, 125/5, 250/10 (≥12 years) 1 inhalation o.d (≥4 years) Accuhaler: 1 inhalation b.d Evohaler: 2 inhalations b.d (≥6 years) 1-2 inhalations b.d (≥18 years) 1-2 inhalations b.d (≥12 years) 2 inhalations b.d Prescribing information Prescribing information The above doses are maintenance doses only and may vary according to age; o.d-once daily; b.d-twice daily Please see respective SPC’s for full dosing schedule References 1. 2. 3. 4. 5. 6. 7. 8. Relvar Ellipta 92/22 Summary of Product Characteristics. GlaxoSmithKline, 2013. Last accessed date August 2014 Seretide Accuhaler Summary of Product Characteristics. GlaxoSmithKline, 2013. Last accessed date August 2014 Seretide Evohaler Summary of Product Characteristics. GlaxoSmithKline, 2013. Last accessed date August 2014 Symbicort 100/6 Summary of Product Characteristics. AstraZeneca Ltd, 2013. Last accessed date August 2014. Symbicort 200/6 Summary of Product Characteristics. AstraZeneca Ltd, 2013. Last accessed date August 2014. Symbicort 400/12 Summary of Product Characteristics. AstraZeneca Ltd, 2013. Last accessed date August 2014 Fostair 100/6 Summary of Product Characteristics. Chiesi, 2014. Last accessed date August 2014. Flutiform Summary of Product Characteristics. Napp Pharmaceuticals, 2013. Last accessed date August 2014 K.M.P, September 2014, UK/RESP/0262/14g